- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about JNJ
Recent news which mentions JNJ
Tickers
JNJ
From Motley Fool
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
January 22, 2025
From Benzinga
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
From Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
January 22, 2025
Tickers
JNJ
From Motley Fool
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
January 22, 2025
From Benzinga
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
January 22, 2025
From Benzinga
US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch
January 22, 2025
From Benzinga
Earnings Scheduled For January 22, 2025
January 22, 2025
From Benzinga
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
January 22, 2025
From Benzinga
From Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
January 22, 2025
From Benzinga
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
January 21, 2025
From Benzinga
From Benzinga
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
January 21, 2025
From Benzinga
From Motley Fool
From Motley Fool
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
January 21, 2025
From Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
January 20, 2025
From Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
January 19, 2025
From Benzinga
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
January 18, 2025
From Motley Fool
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
January 18, 2025
From Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
January 17, 2025
From Benzinga
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
January 17, 2025
From Motley Fool
Got $200? 2 Dividend Stocks to Buy and Hold Forever
January 15, 2025
From Motley Fool
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
January 14, 2025
From Benzinga
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
January 13, 2025
From Benzinga
2 Beaten-Down Dividend Stocks to Buy in 2025
January 13, 2025
From Motley Fool
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
January 10, 2025
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.